FOCUS ON CANCER AND HIV
Argos’ initial focus is on cancer and HIV. Argos’ personalized
immunotherapeutics are applicable to nearly all cancers, including hematologic
malignancies, and to the majority of new cancer patients.
immunotherapy approach could enable a more effective and potentially
safer treatment option to a large percentage of patients around the globe.
The Company estimates that a personalized immunotherapy product to
treat cancers and/or HIV could have multi-billion dollar revenue potential.
ON OTHER INFECTIOUS DISEASES
Beyond HIV, Argos’ patented technology
offers the potential to create personalized immunotherapies for other
infectious diseases resistant to current therapies. Chronic infections
such as hepatitis C (HCV) represent some of the largest and most significant
areas of unmet medical need.
FOCUS ON TRANSPLANTATION AND Inflammatory and AUTOIMMUNE DISORDERS
Through its proprietary
expertise in the biology of dendritic cells, Argos has recognized potential
applications for other disease areas. Argos is developing soluble CD83
protein as a novel first-in-class therapy to prevent transplantation
rejection and treat certain inflammatory and autoimmune diseases. According to the Organ
Procurement and Transplantation Network, about 25,000 organ transplants
take place per year. The rate of transplant rejection varies by organ
and ranges from 30 to 60 percent, creating a considerable need for effective
prevention and treatment. Current transplant rejection treatment includes
immunosuppressive agents with heavy side effects. In contrast, Argos’ CD83
protein selectively blocks immunoresponse without causing total immunosuppression.
In addition to transplantation rejection, CD83 is potentially a treatment
for a number of inflammatory and autoimmune diseases, including irritable bowel disease, multiple sclerosis and
diabetes, for which there are large unmet medical needs. Argos is developing its anti-Interferon-alpha monoclonal antibody for the treatment of systemic lupus erythematosus (SLE) for which there is a clear large unmet medical need.